CAMP4 Therapeutics (NASDAQ:CAMP) Downgraded by Wall Street Zen to Sell

Wall Street Zen cut shares of CAMP4 Therapeutics (NASDAQ:CAMP) from a hold rating to a sell rating in a research note published on Saturday morning,Wall Street Zen reports.

CAMP has been the subject of a number of other reports. Oppenheimer initiated coverage on shares of CAMP4 Therapeutics in a research note on Monday, October 5th. They set an “outperform” rating and a $15.00 price target for the company. Weiss Ratings lowered CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 2nd. Chardan Capital cut their target price on CAMP4 Therapeutics from $6.50 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, September 29th. Zacks Research upgraded CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, August 17th. Finally, Piper Sandler restated an “overweight” rating and set a $15.00 price objective (up from $12.00) on shares of CAMP4 Therapeutics in a report on Friday, August 14th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $10.86.

CAMP4 Therapeutics Stock Performance

Shares of CAMP4 Therapeutics stock opened at $3.77 on Friday. The stock has a market cap of $236.57 million, a price-to-earnings ratio of -1.63 and a beta of 0.27. The stock has a 50 day moving average price of $4.20 and a 200-day moving average price of $4.21. CAMP4 Therapeutics has a one year low of $2.86 and a one year high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last issued its quarterly earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.34). CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%. The company had revenue of $1.78 million during the quarter. Sell-side analysts predict that CAMP4 Therapeutics will post -0.66 earnings per share for the current fiscal year.

Insider Transactions at CAMP4 Therapeutics

In other CAMP4 Therapeutics news, Director Andrew J. Schwab sold 400,000 shares of the firm’s stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $4.04, for a total transaction of $1,616,000.00. Following the transaction, the director directly owned 2,033,270 shares in the company, valued at $8,214,410.80. This trade represents a 16.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Kelly Gold bought 10,000 shares of the firm’s stock in a transaction on Monday, August 31st. The shares were purchased at an average cost of $3.96 per share, with a total value of $39,600.00. Following the completion of the transaction, the chief financial officer owned 10,000 shares in the company, valued at $39,600. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have purchased 46,031 shares of company stock valued at $99,051 and have sold 593,613 shares valued at $2,504,037. Corporate insiders own 21.69% of the company’s stock.

Hedge Funds Weigh In On CAMP4 Therapeutics

Several institutional investors have recently made changes to their positions in CAMP. Jupiter Topco LLC purchased a new stake in CAMP4 Therapeutics in the second quarter worth about $27,581,000. 5AM Venture Management LLC purchased a new position in CAMP4 Therapeutics during the 2nd quarter valued at about $25,647,928. Trails Edge Capital Partners LP bought a new stake in shares of CAMP4 Therapeutics in the 2nd quarter valued at about $8,446,935. BlackRock Inc. purchased a new stake in shares of CAMP4 Therapeutics in the 2nd quarter worth approximately $7,185,000. Finally, EcoR1 Capital LLC purchased a new stake in shares of CAMP4 Therapeutics in the 4th quarter worth approximately $1,992,000.

About CAMP4 Therapeutics

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing RNA-based medicines for genetic diseases caused by insufficient production of essential proteins. The company’s approach is designed to increase expression of a patient’s existing genes rather than replace or edit them.

CAMP4 uses its RegRNA platform to identify regulatory elements in messenger RNA and develop RNA activators, including small activating RNAs, that may stimulate production of targeted proteins.